[Biotherapies to treat necrotizing vasculitis].
Inserm U 1060, service de médecine interne, hôpital Cochin, université Paris Descartes, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France. loic.guillevin@cch.aphp.fr
L
L
Guillevin
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D001691:Biological Therapy / Q000639:trends; D003879:Dermatologic Agents / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use; D000069285:Infliximab; D009336:Necrosis; D010951:Plasma Exchange; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use; D014657:Vasculitis / Q000188:drug therapy* / Q000473:pathology* / Q000628:therapy
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D003879:Dermatologic Agents; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; D000069285:Infliximab